William Westlin, Ph.D., is currently Executive Vice President of Research and Development at eGenesis where he brings extensive biotech experiences to bear on fulfilling the promise of developing genetically engineered biocompatible organs to address the global organ transplant crisis through xenotransplantation. Prior to joining eGenesis, Dr. Westlin was Senior Vice President of Research and Early Development at both Nimbus Therapeutics and Avila Therapeutics where he led teams that identified cutting edge therapeutics and advanced programs to early development using creative first-in-human study designs to generate clinical proof-of-concept. As part of the executive leadership teams, Dr. Westlin helped establish several critical partnerships with Sanofi, Celgene, Clovis Oncology, and Gilead Sciences. Prior to joining Avila, Dr. Westlin was Senior Vice President of Preclinical Research at Praecis Pharmaceuticals responsible for drug discovery and early translational development studies in pharmacology, DMPK, analytical pharmacology, drug safety assessment, and early clinical development in support of the immune, inflammation, and oncology programs. Prior to joining Praecis, Dr. Westlin held positions of increasing responsibility over a ten-year period in the Departments of Immunology, Molecular Pharmacology, and Oncology with Searle/Pharmacia. Dr. Westlin earned his B.S. in Biology from the University of Richmond, MS and PhD degrees in Pharmacology from New York Medical College and completed a Post-Doctoral Research Fellowship in Vascular Biology at Harvard Medical School. Dr. Westlin has more than 65 publications and patents and has been an invited speaker at many national and international meetings.